<DOC>
	<DOCNO>NCT01306643</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy idelalisib ( GS-1101 , CAL-101 ) participants previously treat indolent non-Hodgkin lymphoma ( iNHL ) . Eligible patient initiate oral therapy idelalisib start dose 150 mg twice per day . Treatment idelalisib continue compliant participant twelve 28-day cycle idelalisib . Participants appear benefit treatment completion 12 cycle treatment idelalisib may eligible participation long-term safety extension study idelalisib .</brief_summary>
	<brief_title>Safety Efficacy Study Idelalisib ( GS-1101 , CAL-101 ) Patients With Previously Treated Low-grade Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Previously treat relapsed refractory Bcell iNHL Provide write informed consent Pregnant nursing Active , serious infection require systemic therapy Positive test HIV antibody Active hepatitis B C viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Indolent Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>iNHL</keyword>
	<keyword>NHL</keyword>
	<keyword>CAL-101</keyword>
	<keyword>PI3K</keyword>
	<keyword>Phosphatidylinositol 3-kinase</keyword>
	<keyword>Follicular Lymphoma ( FL )</keyword>
	<keyword>Small Lymphocytic Lymphoma ( SLL )</keyword>
	<keyword>Marginal Zone Lymphoma ( MZL )</keyword>
</DOC>